Skip header and navigation

Narrow By

106 records – page 1 of 6.

After sedation and your child

https://libcat.nshealth.ca/en/permalink/chpams35272
Nova Scotia Health Authority. Emergency Department, Hants Community Hospital. Halifax, NS: Nova Scotia Health Authority , 2017.
Pamphlet Number
1389
Available Online
View Pamphlet
This pamphlet provides details on how to care for your child after they have received sedation at the Hants Community Hospital. Specific instructions are given for how to keep your child safe and when they may start eating again after sedation.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Emergency Department, Hants Community Hospital
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2017
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Child
Conscious Sedation
Subjects (LCSH)
Drugs
Children
Conscious sedation
Specialty
Hants Community Hospital
Medications
Abstract
This pamphlet provides details on how to care for your child after they have received sedation at the Hants Community Hospital. Specific instructions are given for how to keep your child safe and when they may start eating again after sedation.
Responsibility
Prepared by: Emergency Department, Hants Community Hospital
Pamphlet Number
1389
Less detail

American Psychiatric Association Publishing textbook of psychopharmacology

https://libcat.nshealth.ca/en/permalink/provcat37956
edited by Alan F. Schatzberg, Charles B. Nemeroff. (Fifth edition) --Arlington, VA: American Psychiatric Association Publishing , 2017.
Access
Access to this online resource is restricted to IWK Health Centre employees working from inside the hospital network.
Location
Online
Other Authors
Schatzberg, Alan F
Nemeroff, Charles B
Other Authors
American Psychiatric Association
Responsibility
edited by Alan F. Schatzberg, Charles B. Nemeroff
Edition
Fifth edition
Place of Publication
Arlington, VA
Publisher
American Psychiatric Association Publishing
Date of Publication
2017
ISBN
9781615371228
9781585625239 (print)
Subjects (MeSH)
Mental Disorders - drug therapy
Psychotropic Drugs - pharmacology
Psychotropic Drugs - therapeutic use
Access
Access to this online resource is restricted to IWK Health Centre employees working from inside the hospital network.
Format
e-Book
Location
Online
Less detail

The American Psychiatric Publishing textbook for psychopharmacology

https://libcat.nshealth.ca/en/permalink/provcat33188
edited by Alan F. Schatzberg, Charles B. Nemeroff. (5th ed.) --Arlington, VA: American Psychiatric Association Publishing , c2017.
Available Online
View e-Book
Location
Online
The American Psychiatric Association Publishing Textbook of Psychopharmacology boasts a long and unassailable reputation as a classic, providing a clearly written, meticulously cross-referenced, and user-friendly guide to this swiftly evolving field. This new 5th Edition has been thoroughly updated in the context of the latest research and reflects the introduction of DSM-5. The chapter authors were carefully selected for their expertise, and the editors have ensured that the resulting text is …
Available Online
View e-Book
Other Authors
Schatzberg, Alan F.
Nemeroff, Charles B.
Responsibility
edited by Alan F. Schatzberg, Charles B. Nemeroff
Edition
5th ed.
Alternate Title
Textbook of psychopharmacology
Place of Publication
Arlington, VA
Publisher
American Psychiatric Association Publishing
Date of Publication
c2017
Physical Description
[1823 p.]
ISBN
9781615371228
Subjects (MeSH)
Mental Disorders - drug therapy
Psychopharmacology
Psychotropic Drugs - pharmacology
Psychotropic Drugs - therapeutic use
Abstract
The American Psychiatric Association Publishing Textbook of Psychopharmacology boasts a long and unassailable reputation as a classic, providing a clearly written, meticulously cross-referenced, and user-friendly guide to this swiftly evolving field. This new 5th Edition has been thoroughly updated in the context of the latest research and reflects the introduction of DSM-5. The chapter authors were carefully selected for their expertise, and the editors have ensured that the resulting text is consistent in style and approach across topics and sections. The journey -- beginning with the core principles of molecular biology, genetics and genomics, and pharmacokinetics, continuing with the myriad classes of psychopharmacological agents, and ultimately arriving at the treatment of major psychiatric disorders as well as of specific age groups and circumstances -- is logical, easy to follow, and authoritative. Both physicians still in training and clinicians who regularly prescribe psychotropic medications will find the up-to-date and specific guidance on drug selection invaluable. The American Psychiatric Association Publishing Textbook of Psychopharmacology remains an essential, and trusted, companion.
Format
e-Book
Location
Online
Less detail

Anticoagulation Clinic : return appointment

https://libcat.nshealth.ca/en/permalink/chpams34536
Capital Health (N.S.). Anticoagulation Clinic. Halifax, NS: Capital Health , 2012.
Pamphlet Number
0451
Available Online
View Pamphlet
Directions are provided for your yearly appointment at the Anticoagulation Clinic, VG Site, QEII.
Available Online
View Pamphlet
Corporate Author
Capital Health (N.S.). Anticoagulation Clinic
Place of Publication
Halifax, NS
Publisher
Capital Health
Date of Publication
2012
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Hematology
Medication
Subjects (LCSH)
Hematology
Drugs
Specialty
Medications
Abstract
Directions are provided for your yearly appointment at the Anticoagulation Clinic, VG Site, QEII.
Responsibility
Anticoagulation Clinic
Pamphlet Number
0451
Less detail

Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents

https://libcat.nshealth.ca/en/permalink/provcat40067
Michael W. Jann, Scott R. Penzak, Lawrence J. Cohen, editors. (1st ed.) --Cham: Springer International Publishing : Imprint: Adis , c2016.
Available Online
View e-Book
Location
Online
This book is a comprehensive resource on psychotropic medications, detailing the latest methods for defining their characteristics, their use in different patient populations, and drug-drug interactions; an important collection of information for clinicians, students, researchers, and members of the pharmaceutical industry alike. The first section provides the foundational principles of these drugs. Mathematical modeling of parameters that affect their entryto,and exit from, the central nervous…
Available Online
View e-Book
Other Authors
Jann, Michael W
Penzak, Scott R
Cohen, Lawrence J
Responsibility
Michael W. Jann, Scott R. Penzak, Lawrence J. Cohen, editors
Edition
1st ed.
Place of Publication
Cham
Publisher
Springer International Publishing : Imprint: Adis
Date of Publication
c2016
Physical Description
1 online resource (xiv, 601 p. : 100 illus., 50 illus. in color)
ISBN
9783319278834
9783319278810 (print ed.)
Subjects (MeSH)
Drug Interactions
Psychotropic Drugs - pharmacokinetics
Psychotropic Drugs - pharmacology
Abstract
This book is a comprehensive resource on psychotropic medications, detailing the latest methods for defining their characteristics, their use in different patient populations, and drug-drug interactions; an important collection of information for clinicians, students, researchers, and members of the pharmaceutical industry alike. The first section provides the foundational principles of these drugs. Mathematical modeling of parameters that affect their entryto,and exit from, the central nervous system (CNS) compartment are presented on an individual basis and then applied to target populations with specific disease states. Methods and characteristics that inform the transfer of these drugs from the laboratory bench to use in patient care are discussed, including imaging techniques, genetics and physiological barriers, such as the blood-brain barrier. The second section describes the characteristics of specific agents,nominally arranged intodifferent therapeutic categories and with reference crossover use in different disease states. The pharmacologic characteristics of different drug formulations are explored in the context of their ability to improve patient adherence. The third section focuses on drug-drug interactions.Psychotropic medications from different categories are frequently prescribed together, or alongside medications used to treat comorbid conditions, and the information provided is directly relevant to the clinic, as a result. The clinical application of pharmacokinetics and pharmacodynamics of CNS agents has made significant progress over the past 50 years and new information is reported by numerous publications in psychiatry, neurology, and pharmacology. Our understanding of the interrelationship between these medications, receptors, drug transporters, as well as techniques for measurement and monitoring their interactions, is frequently updated. However, with information presented on a host of different platforms, and in different formats, obtaining the full picture can be difficult. This title aims to collate this information into a single source that can be easily interpreted and applied towards patient care by the clinical practitioner, and act as a reference for all others who have an interest in psychopharmacological agents.
Contents
Section 1. General Pharmacokinetic and Pharmacodynamic Principles of Psychopharmacological Agents -- 1. Pharmacokinetic Properties -- 2. Pharmacodynamic Properties -- 3. PET Scan and Other Biomarkers -- 4. Population Pharmacokinetics -- 5. Drug Transporters (esp. Blood Brain Barrier) -- 6. Pharmacogenomics -- Section 2. Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Drug Classes -- 7. Antipsychotics: oral typical agents, oral atypical agents, and long-acting injectable (LAI) antipsychotics -- 8. Mood Stabilizers -- 9. Antidepressants: tricyclics, selective serotonergic reuptake inhibitors, serotonergic noradrenergic reuptake inhibitors, monoamine oxidase inhibitors, and other antidepressants -- 10. Benzodiazepines and Other Sedative Hypnotics/Anxiolytics -- 11. Opioid Analgesics -- 12. Stimulants and Other Non-Stimulants for ADHD -- 13. Cholinesterase Inhibitors and Other Antidementa Agents -- 14. Anti-Addiction Agents -- 15. Anesthetics -- Section 3. Clinically Significant Drug Interactions With Psychopharmacological Agents -- 16. Antipsychotics -- 17. Mood Stabilizers -- 18. Antidepressants -- 19. Benzodiazepines and Other Sedative Hypnotics/Anxiolytics -- 20. Opioid Analgesics -- 21. Stimulants and Other Non-Stimulants for ADHD -- 22. Cholinesterase Inhibitors and Other Antidementa Agents -- 23. Anti-Addiction Agents -- 24. Anesthetics.
Format
e-Book
Location
Online
Less detail

Aripiprazole (Abilify, Abilify Maintena)

https://libcat.nshealth.ca/en/permalink/chpams35626
Nova Scotia Health Authority. Central Zone. Pharmacy Services, QEII. Halifax, NS: Nova Scotia Health Authority , 2016.
Pamphlet Number
1627
Available Online
View Pamphlet
Aripiprazole is most often used to treat psychosis. It is also used to treat mania and sometimes depression. Possible side effects as well as a list of symptoms that it helps to relieve are reviewed. How quickly it starts working, how long to take it, and other general information is provided.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Pharmacy Services, QEII
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2016
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([2] p.) : digital, PDF file
Subjects (MeSH)
Aripiprazole
Subjects (LCSH)
Antipsychotic drugs
Specialty
Medications
Abstract
Aripiprazole is most often used to treat psychosis. It is also used to treat mania and sometimes depression. Possible side effects as well as a list of symptoms that it helps to relieve are reviewed. How quickly it starts working, how long to take it, and other general information is provided.
Responsibility
Prepared by: Pharmacy Services, QEII
Pamphlet Number
1627
Less detail

Bone drugs in pediatrics : efficacy and challenges

https://libcat.nshealth.ca/en/permalink/provcat33833
Gordon L. Klein, editor. --New York: Springer , c2014.
Available Online
View e-Book
Location
Online
Bone Drugs in Pediatrics brings together in one place the evidence for the use of certain drugs in the treatment and prevention of bone loss in children, as well as the reservations still present in the pediatric community regarding their use. Beginning with a discussion of developmental pharmacokinetics and drug development for pediatric diseases where bone loss occurs, such as osteogenesis imperfecta, the physiology of pediatric bone and how best to monitor the safety and efficacy of these dr…
Available Online
View e-Book
Other Authors
Klein, Gordon L.
Responsibility
Gordon L. Klein, editor
Place of Publication
New York
Publisher
Springer
Date of Publication
c2014
Physical Description
1 online resource (xiii, 233 pages)
ISBN
9781489974365 (electronic bk.)
9781489974358
Subjects (MeSH)
Bone Density Conservation Agents
Bone Diseases - drug therapy
Growth Hormone - adverse effects
Subjects (LCSH)
Bone diseases in children - Treatment
Drugs - Effectiveness
Pediatric pharmacology
Abstract
Bone Drugs in Pediatrics brings together in one place the evidence for the use of certain drugs in the treatment and prevention of bone loss in children, as well as the reservations still present in the pediatric community regarding their use. Beginning with a discussion of developmental pharmacokinetics and drug development for pediatric diseases where bone loss occurs, such as osteogenesis imperfecta, the physiology of pediatric bone and how best to monitor the safety and efficacy of these drugs is presented. The pros and cons of utilizing the drugs themselves - such as bisphosphonates, anti-resorptives and anabolic agents - within the pediatric population are carefully considered, with an eye toward safe and effective integration. The potential use of drugs infuture treatment is also highlighted. On the whole, Bone Drugs in Pediatrics is a cogent presentation of the ongoing debate surrounding the potential for pharmacological interventions in pediatric bone loss.
Contents
Introduction -- Developmental Pharmacokinetics: Drug Disposition Relative to Age -- Drug Development for Pediatric Diseases with Bone Loss -- Paediatric Bone Physiology and Monitoring Safety and Efficacy of Bone Drugs in Children -- Bisphosphonates in Osteogenesis Imperfecta -- Use of Bisphosphonates in Genetic Diseases Other Than Osteogenesis Imperfecta -- Bisphosphonates in Pediatric Burn Injury -- Growth Hormone and Bone -- Growth Hormone and Oxandrolone in Burned Children -- Pediatric Bone Drugs: Calcium and Vitamin D -- Pediatric Maxillofacial Conditions and Drugs -- Newer Adult Bone Drugs -- Conclusion: Whither (or Wither?) the Pharmacology on Pediatric Bone?
Format
e-Book
Location
Online
Less detail

Brain science and psychological disorders : therapy, psychotropic drugs, and the brain

https://libcat.nshealth.ca/en/permalink/provcat22787
Kraly, F. Scott. --New York, NY: W.W. Norton , 2006.
Call Number
WL 103.5 K89b 2006
Location
Nova Scotia Hospital
Call Number
WL 103.5 K89b 2006
Author
Kraly, F. Scott
Place of Publication
New York, NY
Publisher
W.W. Norton
Date of Publication
2006
Physical Description
210 p.
ISBN
0393704653
Subjects (MeSH)
Neuropsychiatry
Neuropsychology
Brain Diseases - diagnosis
Psychotropic Drugs
Format
Book
Location
Nova Scotia Hospital
Loan Period
3 weeks
Less detail

Cefazolin for peritonitis in peritoneal dialysis

https://libcat.nshealth.ca/en/permalink/chpams35860
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2017.
Pamphlet Number
1818
Available Online
View Pamphlet
If you have peritonitis (an infection in your peritoneum), your renal team may tell you to take an antibiotic, such as cefazolin. This pamphlet explains some of the possible side effects of cefazolin, how to give yourself this drug, and how to store this drug. What to do if you have questions and a list of things to remember are also provided.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Alternate Title
Cefazolin for peritonitis in PD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2017
Format
Pamphlet
Language
English
Physical Description
1 electronic document (5 p.) : digital, PDF file
Subjects (MeSH)
Medications
Peritonitis
Peritoneal Dialysis
Subjects (LCSH)
Drugs
Peritonitis
Peritoneal dialysis
Specialty
Nephrology
Medications
Abstract
If you have peritonitis (an infection in your peritoneum), your renal team may tell you to take an antibiotic, such as cefazolin. This pamphlet explains some of the possible side effects of cefazolin, how to give yourself this drug, and how to store this drug. What to do if you have questions and a list of things to remember are also provided.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1818
Less detail

Ceftazidime for peritonitis in peritoneal dialysis

https://libcat.nshealth.ca/en/permalink/chpams35861
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2017.
Pamphlet Number
1819
Available Online
View Pamphlet
If you have peritonitis (an infection in your peritoneum), your renal team may tell you to take an antibiotic, such as ceftazidime. This pamphlet explains some of the possible side effects of ceftazidime, how to give yourself this drug, and how to store this drug. What to do if you have questions and a list of things to remember are also provided.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Alternate Title
Ceftazidime for peritonitis in PD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2017
Format
Pamphlet
Language
English
Physical Description
1 electronic document (5 p.) : digital, PDF file
Subjects (MeSH)
Medications
Peritonitis
Peritoneal Dialysis
Subjects (LCSH)
Drugs
Peritonitis
Peritoneal dialysis
Specialty
Nephrology
Medications
Abstract
If you have peritonitis (an infection in your peritoneum), your renal team may tell you to take an antibiotic, such as ceftazidime. This pamphlet explains some of the possible side effects of ceftazidime, how to give yourself this drug, and how to store this drug. What to do if you have questions and a list of things to remember are also provided.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1819
Less detail

Chemotherapy in Psychiatry : Pharmacologic Basis of Treatments for Major Mental Illness

https://libcat.nshealth.ca/en/permalink/provcat32367
Ross J. Baldessarini. (3rd ed.) --New York, NY: Springer , c2013.
Available Online
View e-Book
Location
Online
Use of psychotropic drugs has come to dominate clinical practice in psychiatry worldwide, perhaps owing largely to perceived simplicity, ease of use, and apparent efficiency, as well as apparent cost-effectiveness of such treatments. Nevertheless, medicinal treatments for patients with psychiatric disorders are but one component of comprehensive clinical care of complex human problems. Extensively updated since its second edition in 1985, Chemotherapy in Psychiatry, Third Edition, again addres…
Available Online
View e-Book
Author
Baldessarini, Ross J
Responsibility
Ross J. Baldessarini
Edition
3rd ed.
Place of Publication
New York, NY
Publisher
Springer
Date of Publication
c2013
Physical Description
1 online resource (xi, 269 p. : 36 ill.)
ISBN
9781461437109
Subjects (MeSH)
Mental Disorders - drug therapy
Psychopharmacology
Psychotropic Drugs - therapeutic use
Subjects (LCSH)
Neurosciences
Pharmacy
Psychiatry
Abstract
Use of psychotropic drugs has come to dominate clinical practice in psychiatry worldwide, perhaps owing largely to perceived simplicity, ease of use, and apparent efficiency, as well as apparent cost-effectiveness of such treatments. Nevertheless, medicinal treatments for patients with psychiatric disorders are but one component of comprehensive clinical care of complex human problems. Extensively updated since its second edition in 1985, Chemotherapy in Psychiatry, Third Edition, again addresses basic aspects of modern psychopharmacology and clinical applications of drugs used in the treatment of major psychiatric disorders, with major emphasis on psychotic, bipolar, and depressive disorders. The presentation covers descriptions of the main classes of psychotropic drugs, selected information concerning their known action mechanisms and metabolic disposition, and their clinical applications for acute illnesses and to prevent recurrences and long-term morbidity. Also covered are limitations and adverse effects of each type of agent, with emphasis on the fact that all psychotropic medicines have adverse effects that range from annoying to potentially lethal. Chemotherapy in Psychiatry, Third Edition, outlines the need to balance benefits and risks at the level of individual persons. Authoritative, and an important contribution to the literature, Chemotherapy in Psychiatry, Third Edition is an invaluable resource for physicians, scientists, trainees, and policymakers.
Contents
Modern psychopharmacology -- Antipsychotic agents -- Mood-stabilizing agents -- Antidepressant-antianxiety agents -- Status and prospects for psychopharmacology.
Format
e-Book
Location
Online
Less detail

Clinical handbook of psychotropic drugs

https://libcat.nshealth.ca/en/permalink/provcat42420
Ric M. Procyshyn, principal editor ; Kalyna Z. Bezchlibnyk-Butler, co-editor ; J. Joel Jeffries, co-editor. (22nd ed.) --Boston, MA: Hogrefe Publishing , c2017.
Call Number
QV 77 C641 2017 REF
Location
Nova Scotia Hospital
Cape Breton Regional
Aberdeen Hospital
Dickson Building
Halifax Infirmary
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals. Independent, unbiased. Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions) for a quick overview of treatment options. Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactio…
Call Number
QV 77 C641 2017 REF
Other Authors
Procyshyn, Ric M.
Bezchlibnyk-Butler, Kalyna Z.
Jeffries, J. Joel
Responsibility
Ric M. Procyshyn, principal editor ; Kalyna Z. Bezchlibnyk-Butler, co-editor ; J. Joel Jeffries, co-editor
Edition
22nd ed.
Alternate Title
Psychotropic drugs
CHPD
Place of Publication
Boston, MA
Publisher
Hogrefe Publishing
Date of Publication
c2017
Physical Description
431 p.
ISBN
9781616764968
1616764961
Subjects (MeSH)
Psychotropic Drugs - administration and dosage
Psychotropic Drugs - therapeutic use
Abstract
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals. Independent, unbiased. Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions) for a quick overview of treatment options. Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug. Potential interactions and side effects summarized in comparison charts. With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek. Clearly written patient information sheets available for download as printable PDF files.
Contents
Antidepressants -- Selective Serotonin Reuptake Inhibitors (SSRI) -- Norepinephrine Dopamine Reuptake Inhibitor (NDRI) -- Serotonin Norepinephrine Reuptake Inhibitor (SNRI) -- Serotonin-2 Antagonists/Reuptake Inhibitors (SARI) -- Serotonin-1A Agonist/Serotonin Reuptake Inhibitor -- Serotonin Stimulator/Serotonin Modulator -- Noradrenergic/Specific Serotonergic Antidepressants (NaSSA) -- Nonselective Cyclic Antidepressants -- Monoamine Oxidase Inhibitors -- Reversible Inhibitor of MAO-A (RIMA) -- Irreversible Monoamine Oxidase (A&B) Inhibitors (MAOIs) -- Irreversible MAO-B Inhibitor -- Effects of Antidepressants on Neurotransmitters/Receptors -- Pharmacological Effects of Antidepressants on Neurotransmitters/Receptors -- Frequency of Adverse Reactions to Antidepressants at Therapeutic Doses -- Antidepressant Doses and Pharmacokinetics -- Switching Antidepressants -- Antidepressant Augmentation Strategies -- Electroconvulsive Therapy (ECT) -- Bright Light Therapy (BLT) -- Repetitive Transcranial Magnetic Stimulation (rTMS) -- Antipsychotics -- "Second-Generation" Antipsychotics/SGAs -- "Third-Generation" Antipsychotic/TGA -- "First-Generation" Antipsychotics/FGAs -- Effects of Antipsychotics on Neurotransmitters/Receptors -- Pharmacological Effects of Antipsychotics on Neurotransmitters/Receptor Subtypes -- Relative Tolerability Profiles of Antipsychotics -- Frequency (%) of Adverse Reactions to Antipsychotics at Therapeutic Doses -- Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting Injections) -- Comparison of Long-Acting IM Antipsychotics -- Switching Antipsychotics -- Antipsychotic Augmentation Strategies -- Antipsychotic-Induced Extrapyramidal Side Effects and Their Management -- Extrapyramidal Adverse Effects of Antipsychotics -- Treatment Options for Extrapyramidal Side Effects -- Effects on Extrapyramidal Symptoms -- Comparison of Agents for Treating Acute Extrapyramidal Side Effects -- Doses and Pharmacokinetics of Agents for Treating Acute Extrapyramidal Side Effects -- Anxiolytic (Antianxiety) Agents -- Benzodiazepines -- Comparison of the Benzodiazepines -- Buspirone -- Hypnotics/Sedatives -- L-Tryptophan -- Comparison of Hypnotics/Sedatives -- Mood Stabilizers -- Lithium -- Anticonvulsants -- Comparison of Anticonvulsants -- Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic Doses -- Drugs for ADHD -- Psychostimulants -- Atomoxetine -- Comparison of Drugs for ADHD -- a2 agonists -- Augmentation Strategies in ADHD -- Drugs for Treatment of Dementia -- Cholinesterase Inhibitors -- Memantine -- Comparison of Drugs for Treatment of Dementia -- Sex-Drive Depressants -- Comparison of Sex-Drive Depressants -- Drugs of Abuse -- Alcohol -- Stimulants -- Hallucinogens -- Opioids -- Inhalants/Aerosols -- Gamma-hydroxybutyrate (GHB)/Sodium Oxybate -- Flunitrazepam (Rohypnol) -- Nicotine/Tobacco -- Treatment of Substance Use Disorders -- Acamprosate -- Disulfiram -- Naltrexone -- Buprenorphine -- Methadone -- Pharmacotherapy for Nicotine/Tobacco Use Dependence -- Unapproved Treatments of Psychiatric Disorders -- Adrenergic Agents -- Dopaminergic Agents -- GABA Agents/Anticonvulsants -- Hormones -- NMDA Agents -- Miscellaneous -- Natural Health Products -- Ginkgo Biloba -- Inositol -- Kava Kava -- Melatonin -- Omega-3 Polyunsaturated Fatty Acids -- S-Adenosyl-L-methionine (SAMe) -- St. John's Wort -- Valerian -- Vitamins -- Pharmacogenomic Information for Common Psychotropic Drugs -- Antidepressants -- Antipsychotics -- Mood Stabilizers -- Drugs for Treatment of Dementia -- Opiate Receptor Ligands, Alcohol, Interferon -- Glossary -- Drug use in pregnancy and effects on breast milk -- Patient information sheets -- Appendix: Neuroscience-based nomenclature (NbN) -- Index of drugs.
Format
Book
Publication Type
Handbooks
Location
Nova Scotia Hospital
Cape Breton Regional
Aberdeen Hospital
Dickson Building
Halifax Infirmary
Copies
5
Loan Period
In library use
Less detail

Clinical handbook of psychotropic drugs

https://libcat.nshealth.ca/en/permalink/provcat42494
Ric M. Procyshyn, principal editor ; Kalyna Z. Bezchlibnyk-Butler, co-editor ; J. Joel Jeffries, co-editor. (22nd ed.) --Boston, MA: Hogrefe Publishing , c2017.
Call Number
QV 77 C641 2017
Location
Yarmouth Regional
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals. Independent, unbiased. Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions) for a quick overview of treatment options. Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactio…
Call Number
QV 77 C641 2017
Other Authors
Procyshyn, Ric M.
Bezchlibnyk-Butler, Kalyna Z.
Jeffries, J. Joel
Responsibility
Ric M. Procyshyn, principal editor ; Kalyna Z. Bezchlibnyk-Butler, co-editor ; J. Joel Jeffries, co-editor
Edition
22nd ed.
Alternate Title
Psychotropic drugs
CHPD
Place of Publication
Boston, MA
Publisher
Hogrefe Publishing
Date of Publication
c2017
Physical Description
431 p.
ISBN
9781616764968
1616764961
Subjects (MeSH)
Psychotropic Drugs - administration and dosage
Psychotropic Drugs - therapeutic use
Abstract
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals. Independent, unbiased. Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions) for a quick overview of treatment options. Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug. Potential interactions and side effects summarized in comparison charts. With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek. Clearly written patient information sheets available for download as printable PDF files.
Contents
Antidepressants -- Selective Serotonin Reuptake Inhibitors (SSRI) -- Norepinephrine Dopamine Reuptake Inhibitor (NDRI) -- Serotonin Norepinephrine Reuptake Inhibitor (SNRI) -- Serotonin-2 Antagonists/Reuptake Inhibitors (SARI) -- Serotonin-1A Agonist/Serotonin Reuptake Inhibitor -- Serotonin Stimulator/Serotonin Modulator -- Noradrenergic/Specific Serotonergic Antidepressants (NaSSA) -- Nonselective Cyclic Antidepressants -- Monoamine Oxidase Inhibitors -- Reversible Inhibitor of MAO-A (RIMA) -- Irreversible Monoamine Oxidase (A&B) Inhibitors (MAOIs) -- Irreversible MAO-B Inhibitor -- Effects of Antidepressants on Neurotransmitters/Receptors -- Pharmacological Effects of Antidepressants on Neurotransmitters/Receptors -- Frequency of Adverse Reactions to Antidepressants at Therapeutic Doses -- Antidepressant Doses and Pharmacokinetics -- Switching Antidepressants -- Antidepressant Augmentation Strategies -- Electroconvulsive Therapy (ECT) -- Bright Light Therapy (BLT) -- Repetitive Transcranial Magnetic Stimulation (rTMS) -- Antipsychotics -- "Second-Generation" Antipsychotics/SGAs -- "Third-Generation" Antipsychotic/TGA -- "First-Generation" Antipsychotics/FGAs -- Effects of Antipsychotics on Neurotransmitters/Receptors -- Pharmacological Effects of Antipsychotics on Neurotransmitters/Receptor Subtypes -- Relative Tolerability Profiles of Antipsychotics -- Frequency (%) of Adverse Reactions to Antipsychotics at Therapeutic Doses -- Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting Injections) -- Comparison of Long-Acting IM Antipsychotics -- Switching Antipsychotics -- Antipsychotic Augmentation Strategies -- Antipsychotic-Induced Extrapyramidal Side Effects and Their Management -- Extrapyramidal Adverse Effects of Antipsychotics -- Treatment Options for Extrapyramidal Side Effects -- Effects on Extrapyramidal Symptoms -- Comparison of Agents for Treating Acute Extrapyramidal Side Effects -- Doses and Pharmacokinetics of Agents for Treating Acute Extrapyramidal Side Effects -- Anxiolytic (Antianxiety) Agents -- Benzodiazepines -- Comparison of the Benzodiazepines -- Buspirone -- Hypnotics/Sedatives -- L-Tryptophan -- Comparison of Hypnotics/Sedatives -- Mood Stabilizers -- Lithium -- Anticonvulsants -- Comparison of Anticonvulsants -- Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic Doses -- Drugs for ADHD -- Psychostimulants -- Atomoxetine -- Comparison of Drugs for ADHD -- a2 agonists -- Augmentation Strategies in ADHD -- Drugs for Treatment of Dementia -- Cholinesterase Inhibitors -- Memantine -- Comparison of Drugs for Treatment of Dementia -- Sex-Drive Depressants -- Comparison of Sex-Drive Depressants -- Drugs of Abuse -- Alcohol -- Stimulants -- Hallucinogens -- Opioids -- Inhalants/Aerosols -- Gamma-hydroxybutyrate (GHB)/Sodium Oxybate -- Flunitrazepam (Rohypnol) -- Nicotine/Tobacco -- Treatment of Substance Use Disorders -- Acamprosate -- Disulfiram -- Naltrexone -- Buprenorphine -- Methadone -- Pharmacotherapy for Nicotine/Tobacco Use Dependence -- Unapproved Treatments of Psychiatric Disorders -- Adrenergic Agents -- Dopaminergic Agents -- GABA Agents/Anticonvulsants -- Hormones -- NMDA Agents -- Miscellaneous -- Natural Health Products -- Ginkgo Biloba -- Inositol -- Kava Kava -- Melatonin -- Omega-3 Polyunsaturated Fatty Acids -- S-Adenosyl-L-methionine (SAMe) -- St. John's Wort -- Valerian -- Vitamins -- Pharmacogenomic Information for Common Psychotropic Drugs -- Antidepressants -- Antipsychotics -- Mood Stabilizers -- Drugs for Treatment of Dementia -- Opiate Receptor Ligands, Alcohol, Interferon -- Glossary -- Drug use in pregnancy and effects on breast milk -- Patient information sheets -- Appendix: Neuroscience-based nomenclature (NbN) -- Index of drugs.
Format
Book
Publication Type
Handbooks
Location
Yarmouth Regional
Loan Period
3 weeks
Less detail

Clinical handbook of psychotropic drugs

https://libcat.nshealth.ca/en/permalink/provcat23368
[edited by] Adil S. Virani, Kalyna Z. Bezchlibnyk-Butler, J. Joel Jeffries, Ric M. Procyshyn. (19th ed.) --Toronto, ON: Hogrefe Publishing , c2012.
Call Number
QV 77 B574c 2012 REF
Location
Nova Scotia Hospital
Dartmouth General Hospital
Call Number
QV 77 B574c 2012 REF
Other Authors
Virani, Adil
Responsibility
[edited by] Adil S. Virani, Kalyna Z. Bezchlibnyk-Butler, J. Joel Jeffries, Ric M. Procyshyn
Edition
19th ed.
Alternate Title
CHPD
Place of Publication
Toronto, ON
Publisher
Hogrefe Publishing
Date of Publication
c2012
Physical Description
361 p.
ISBN
9780889373952
Subjects (MeSH)
Psychotropic Drugs - administration & dosage
Psychotropic Drugs - therapeutic use
Format
Book
Publication Type
Handbooks
Location
Nova Scotia Hospital
Dartmouth General Hospital
Copies
2
Loan Period
In-library use
Less detail

Clinical handbook of psychotropic drugs for children and adolescents

https://libcat.nshealth.ca/en/permalink/provcat13363
[edited by] Kalyna Z. Bezchlibnyk-Butler and Adil S. Virani. --Cambridge, MA: Hogrefe & Huber , c2004.
Call Number
QV 39 C640 2004
Location
Cape Breton Regional
Call Number
QV 39 C640 2004
Other Authors
Bezchlibnyk-Butler, Kalyna Z., 1947-
Virani, Adil S.
Responsibility
[edited by] Kalyna Z. Bezchlibnyk-Butler and Adil S. Virani
Place of Publication
Cambridge, MA
Publisher
Hogrefe & Huber
Date of Publication
c2004
Physical Description
306 p.
ISBN
9780889372719
0889372713
Subjects (MeSH)
Psychotropic Drugs - Child - administration & dosage
Psychotropic Drugs - Child - therapeutic use
Psychotropic Drugs - Adolescent - administration & dosage
Psychotropic Drugs - Adolescent - therapeutic use
Format
Book
Publication Type
Handbooks
Location
Cape Breton Regional
Copies
2
Less detail

Clinical handbook of psychotropic drugs for children and adolescents

https://libcat.nshealth.ca/en/permalink/provcat38155
[edited by] Kalyna Z. Bezchlibnyk-Butler and Adil S. Virani. (2nd ed.) --Cambridge, MA: Hogrefe & Huber , c2007.
Call Number
QV 77.2 C641 2007
Location
IWK Health Sciences Library
Call Number
QV 77.2 C641 2007
Other Authors
Bezchlibnyk-Butler, Kalyna Z., 1947-
Virani, Adil S.
Responsibility
[edited by] Kalyna Z. Bezchlibnyk-Butler and Adil S. Virani
Edition
2nd ed.
Place of Publication
Cambridge, MA
Publisher
Hogrefe & Huber
Date of Publication
c2007
Physical Description
346 p.
ISBN
9780889373099
0889373094
Subjects (MeSH)
Psychotropic Drugs - Child - administration & dosage
Psychotropic Drugs - Child - therapeutic use
Psychotropic Drugs - Adolescent - administration & dosage
Psychotropic Drugs - Adolescent - therapeutic use
Format
Book
Publication Type
Handbooks
Location
IWK Health Sciences Library
Copies
1
Less detail

Clinical manual of child and adolescent psychopharmacology

https://libcat.nshealth.ca/en/permalink/provcat25856
(2nd ed.) --Washington, DC: American Psychiatric Publishing , c2013.
Call Number
WS 350.2 C641 2013
Location
Halifax Infirmary
Call Number
WS 350.2 C641 2013
Other Authors
McVoy, Molly
Findling, Robert L
Edition
2nd ed.
Place of Publication
Washington, DC
Publisher
American Psychiatric Publishing
Date of Publication
c2013
Physical Description
458 p.
ISBN
9781585624355
Subjects (MeSH)
Mental Disorders - drug therapy
Psychopharmacology - methods
Psychotropic Drugs - therapeutic use
Contents
Developmental aspects of pediatric psychopharmacology / Bendetto Vitiello -- Attention deficit/hyperactivity disorder / Jonathan Posner & Laurence Greenhill -- Disruptive behavior disorders and aggression / Solomon Zaara ... [et al.] -- Anxiety disorders / Moira A. Rynn ... [et al.] -- Major depressive disorder / Boris Birmaher -- Bipolar disorders / Tiffany Thomas ... [et al.] -- Autism and other pervasive developmental disorders / Kimberly A. Stigler ... [et al.] -- Tic disorders / Lawrence Scahill & Aysegul Selcen Guler -- Early schizophrenia and psychotic illnesses / Christopher A. David ... [et al.].
Format
Book
Location
Halifax Infirmary
Copies
1
Loan Period
3 weeks
Less detail

Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials

https://libcat.nshealth.ca/en/permalink/provcat33949
Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom. --Cham, Switzerland: Adis , c2015.
Available Online
View e-Book
Location
Online
This comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarize…
Available Online
View e-Book
Author
Kiang, Tony K. L
Other Authors
Wilby, Kyle John
Ensom, Mary H.H.
Responsibility
Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom
Place of Publication
Cham, Switzerland
Publisher
Adis
Date of Publication
c2015
Physical Description
1 online resource (vii, 146 pages)
ISBN
9783319105277 (electronic bk.)
9783319105260
Subjects (MeSH)
Antimalarials - pharmacokinetics
Drug interactions
Malaria - drug therapy
Subjects (LCSH)
Antimalarials - Pharmacokinetics
Antimalarials - Receptors - Effect of drugs on
Abstract
This comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarized, and potential future research directions / experimentations are also suggested. In addition to the main objective to review the available clinical pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antimalarial drugs on the market today (i.e. chloroquine, amodiaquine, sulfadoxine, pyrimethamine, mefloquine, artemisinin, artemether, artesunate, dihydroartemisinin, artemotil, lumefantrine, primaquine, atovaquone, proguanil, piperaquine and quinine), this book also provides succinct chapter summaries on the epidemiology of malaria infection, diagnosis and therapeutics, in vivo pharmacology and chemistry, preclinical pharmacology, in vitro pharmacodynamics, in vitro reaction phenotyping, and in vitro drug-drug interaction data associated with the identified antimalarial drugs.
Contents
Introduction -- Pharmacology of Recommended Antimalarial Agents -- Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials -- Pharmacokinetic Drug Interactions Affecting Antimalarials -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Drugs -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Antimalarials -- Pharmacodynamic Interactions: Clinical Evidence for Combination Therapy, In Vitro Interactions, and In Vivo Interactions -- Limitations, Future Directions, and Conclusions.
Format
e-Book
Location
Online
Less detail

Clinical psychopharmacology : a practical approach

https://libcat.nshealth.ca/en/permalink/provcat31339
Humberto Marin, Javier I Escóbar. --Hackensack, NJ: World Scientific Pub. Co , c2013.
Available Online
View e-Book
Location
Online
This book aims to provide comprehensive, up-to-date information on psychotropic drugs and inform clinical decisions for the treatment of mental disorders using a problem-solving approach. In order to accomplish these goals, the book has three central characteristics: it is evidence-based; it compares each individual drug with others in the same class and also those used for the same indications rather than describing them separately; it steadily draws practical conclusions and makes recommendat…
Available Online
View e-Book
Author
Marin, Humberto
Other Authors
Escóbar, Javier I
Responsibility
Humberto Marin, Javier I Escóbar
Place of Publication
Hackensack, NJ
Publisher
World Scientific Pub. Co
Date of Publication
c2013
Physical Description
1 online resource (286 p.)
ISBN
9789814343664
Subjects (MeSH)
Mental Disorders - drug therapy
Psychopharmacology
Psychotropic Drugs
Abstract
This book aims to provide comprehensive, up-to-date information on psychotropic drugs and inform clinical decisions for the treatment of mental disorders using a problem-solving approach. In order to accomplish these goals, the book has three central characteristics: it is evidence-based; it compares each individual drug with others in the same class and also those used for the same indications rather than describing them separately; it steadily draws practical conclusions and makes recommendations about how to select and use medications in the treatment of specific mental disorders. More than a textbook, it is meant to serve as a practical tool for professionals working in the mental health field.
Contents
Ch. 1. Absorption, transformation, and elimination of psychotropic medications. -- ch. 2. Neurotransmitters, receptors, and transporters. 2.1. Main types of receptors in the brain. 2.2. Neurotransmitters. 2.3. Neurotransmitter reuptake transporters -- ch. 3. Antipsychotics: a general view of therapeutic and adverse effects. 3.1. Classic antipsychotics. 3.2. New antipsychotics. 3.3. Are the new antipsychotics clinically different from the old ones? 3.4. Current concepts regarding antipsychotic action and the D[symbol] receptor. 3.5. Comparison between typical and atypical antipsychotics. 3.6. Metabolic side effects of antipsychotic drugs. 3.7. Extrapyramidal symptoms of antipsychotics. 3.8. Neuroleptic malignant syndrome. 3.9. Catatonia. 3.10. Antipsychotic-induced hyperprolactinemia. 3.11. Sexual side effects of antipsychotics. 3.12. Antihistamine adverse effects of antipsychotics. 3.13. Anticholinergic adverse effects of antipsychotics: cognitive and peripheral. 3.14. Antipsychotics and the risk of seizures. 3.15. Vascular side effects of antipsychotics. 3.16. Antipsychotics and the risk of malignant arrythmia and sudden cardiac death. 3.17. Antipsychotics and increased morbidity and mortality in patients with dementia. 3.18. Antipsychotics and suicide. 3.19. Antipsychotics and the risk of cancer -- ch. 4. Description of individual antipsychotics. 4.1. Typical antipsychotics. 4.2. Atypical antipsychotics -- ch. 5. Treatment of schizophrenia with antipsychotic medications. 5.1. Choice of an antipsychotic for the initial treatment of schizophrenia. 5.2. Dosing in the initial antipsychotic treatment of schizophrenia. 5.3. How long does it take to respond to an antipsychotic? 5.4. Monitoring antipsychotic treatment. 5.5. Maintenance of antipsychotic treatment of schizophrenia. 5.6. Combination of antipsychotic drugs in schizophrenia ("polypharmacy"). 5.7. Pharmacological management of treatment-resistant schizophrenia. 5.8. Use of long-acting injectable antipsychotics in schizophrenia -- ch. 6. Antidepressants: selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. 6.1. Introduction. 6.2. Pharmacodynamics of SSRIs and SNRIs (receptor affinity). 6.3. Pharmacokinetics of SSRIs and SNRIs. 6.4. Use of SSRIs in mental disorders. 6.5. Use of SNRIs in mental disorders. 6.6. Dosing of SSRIs and SNRIs. 6.7. Adverse effects of SSRIs and SNRIs. 6.8. Discontinuation syndrome with SSRIs and SNRIs. 6.9. Toxicity of SSRIs and SNRIs and serotonin syndrome. 6.10. Precautions with SSRIs and SNRIs. 6.11. Use of SSRIs and SNRIs during pregnancy and lactation -- ch. 7. Bupropion. 7.1. Introduction. 7.2. Pharmacology. 7.3. Approved indications and other possible uses. 7.4. Dosing and available forms of bupropion. 7.5. Side effects and adverse reactions. 7.6. Contraindications, warnings, and precautions. 7.7. Use of bupropion during pregnancy -- Ch. 8. Mirtazapine, trazodone, and nefazodone. 8.1. Mirtazapine. 8.2. Trazodone. 8.3. Nefazodone -- ch. 9. Monoamine oxidase inhibitors and tricyclic antidepressants. 9.1. Monoamine oxidase inhibitors. 9.2. Tricyclic antidepressants -- ch. 10. Individualized treatment of depression. 10.1. Patient factors to consider. 10.2. Second-generation antidepressants: doses and duration. 10.3. Hypnotics and other symptom-specific medications. 10.4. Partial response to antidepressant treatment: what to do? 10.5. No response to initial antidepressant treatment: what to do? 10.6. What about adding atypical antipsychotics in the initial treatment of depression? 10.7. Other non-antidepressant drugs recently tried in depression. 10.8. Once the patient gets better, how to stop antidepressant treatment? -- ch. 11. Benzodiazepines, buspirone, and miscellaneous medications used in anxiety disorders. 11.1. Benzodiazepines. 11.2. Buspirone. 11.3. Antiepileptic drugs. 11.4. Antihistamines. 11.5. Prazosin for nightmares in post-traumatic stress disorder. 11.6. Do antipsychotics have a role in anxiety? 11.7. Beta-blockers -- ch. 12. Medication treatment of anxiety disorders. General considerations prior to starting drug treatment. Other considerations. 12.1. Approved and potential uses of antidepressants and other medications. 12.2. Drug treatment of individual anxiety disorders -- ch. 13. Medications used in the treatment of mania. 13.1. Lithium. 13.2. Antipsychotics. 13.3. Carbamazepine. 13.4. Oxcarbazepine. 13.5. Valproic acid (divalproex, valproate). 13.6. Tamoxifen -- ch. 14. Medications used in bipolar depression, mixed states, and rapid cycling. 14.1. Electroconvulsive therapy. 14.2. Lithium. 14.3. Quetiapine. 14.4. Lamotrigine. 14.5. Valproate. 14.6. Antidepressants. 14.7. Ketamine in bipolar and treatment-resistant depression. 14.8. Pharmacological treatment of mixed states and rapid cycling bipolar disorder -- ch. 15. Medications used in the treatment of insomnia. 15.1. General rules. 15.2. Antihistamines as hypnotics. 15.3. Sedating antidepressants (trazodone and mirtazapine). 15.4. Melatonin receptor agonists. 15.5. GABA receptor agonists -- ch. 16. Medications used in the treatment of attention disorders. 16.1. Stimulant medications (psychostimulants). 16.2. Atomoxetine. 16.3. Bupropion. 16.4. Modafinil. 16.5. [symbol]-adrenergic agonists (guanfacine and clonidine) -- ch. 17. Medications used in the treatment of dementia. 17.1. Side effects. 17.2. Pharmacokinetics. 17.3. Pointers for clinical use -- ch. 18. Medications used in smoking cessation and alcohol use disorders. 18.1. Medications used in the treatment of nicotine dependence (smoking cessation). 18.2. Medications used in the treatment of alcohol use disorders -- ch. 19. Drug-drug interactions. 19.1. Pharmacokinetic drug-drug interactions. 19.2. Pharmacodynamic DDIs involving psychotropic drugs. 19.3. Drug-drug Interactions due to cumulative toxicity. 19.4. Drug-drug interactions related to food supplements and substances of abuse.
Format
e-Book
Location
Online
Less detail

Cocaine and methamphetamine dependence : advances in treatment

https://libcat.nshealth.ca/en/permalink/provcat25432
Kosten, Thomas R,. --Arlington, VA: American Psychiatric Publishing, Inc. , 2012.
Call Number
WM 280 K86c 2012
Location
Nova Scotia Hospital
Call Number
WM 280 K86c 2012
Author
Kosten, Thomas R,
Other Authors
Newton, Thomas F.
De La Garza, Richard
Place of Publication
Arlington, VA
Publisher
American Psychiatric Publishing, Inc.
Date of Publication
2012
Physical Description
216 p.
ISBN
9781585624072
Subjects (MeSH)
Cocaine-Related Disorders
Amphetamines
Behavior Therapy
Psychotropic Drugs - therapeutic use
Format
Book
Location
Nova Scotia Hospital
Loan Period
3 weeks
Less detail

106 records – page 1 of 6.